Your browser doesn't support javascript.
loading
Alcoholic liver disease: Clinical and translational research.
Neuman, Manuela G; Malnick, Stephen; Maor, Yaakov; Nanau, Radu M; Melzer, Ehud; Ferenci, Peter; Seitz, Helmut K; Mueller, Sebastian; Mell, Haim; Samuel, Didier; Cohen, Lawrence B; Kharbanda, Kusum K; Osna, Natalia A; Ganesan, Murali; Thompson, Kyle J; McKillop, Iain H; Bautista, Abraham; Bataller, Ramon; French, Samuel W.
Afiliación
  • Neuman MG; In Vitro Drug Safety and Biotechnology, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: manuela.neuman@utoronto.ca.
  • Malnick S; Division of Gastroenterology, Kaplan Health Sciences Centre, Department of Medicine, Faculty of Medicine, Hebrew University, Rehovot, Israel.
  • Maor Y; Division of Gastroenterology, Kaplan Health Sciences Centre, Department of Medicine, Faculty of Medicine, Hebrew University, Rehovot, Israel.
  • Nanau RM; In Vitro Drug Safety and Biotechnology, Toronto, Ontario, Canada.
  • Melzer E; Division of Gastroenterology, Kaplan Health Sciences Centre, Department of Medicine, Faculty of Medicine, Hebrew University, Rehovot, Israel.
  • Ferenci P; Medical University of Vienna, Austria.
  • Seitz HK; University of Heidelberg, Heidelberg, Germany; Department of Medicine, Gastroenterology and Hepatology, Centre for Alcohol Research, Salem Medical Centre, Heidelberg, Germany.
  • Mueller S; University of Heidelberg, Heidelberg, Germany; Department of Medicine, Gastroenterology and Hepatology, Centre for Alcohol Research, Salem Medical Centre, Heidelberg, Germany.
  • Mell H; Israel Antidrug and Alcohol Authority, Jerusalem, Israel.
  • Samuel D; Liver Transplant Unit, Research Inserm-Paris XI Unit 785, Centre Hepatobiliaire, Hopital Paul Brousse, Villejuif, Paris, France.
  • Cohen LB; Division of Gastroenterology, Sunnybrook Health Sciences Centre and Department of Internal Medicine, University of Toronto, Toronto, Canada.
  • Kharbanda KK; Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Internal Medicine, Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Osna NA; Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Internal Medicine, Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Ganesan M; Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Internal Medicine, Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Thompson KJ; Department of Surgery, Carolinas Medical Center, Charlotte, NC 28203, USA.
  • McKillop IH; Department of Surgery, Carolinas Medical Center, Charlotte, NC 28203, USA.
  • Bautista A; Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.
  • Bataller R; Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • French SW; Harbor-UCLA Medical Center, Torrance, CA, USA.
Exp Mol Pathol ; 99(3): 596-610, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26342547
The present review spans a broad spectrum of topics dealing with alcoholic liver disease (ALD), including clinical research, translational research, pathogenesis and therapies. A special accent is placed on alcohol misuse, as alcohol is a legally commercialized and taxable product. Drinking alcohol, particularly from a young age, is a major health problem. Alcoholism is known to contribute to morbidity and mortality. A systematic literature search was performed in order to obtain updated data (2008-2015). The review is focused on genetic polymorphisms of alcohol metabolizing enzymes and the role of cytochrome p450 2E1 and iron in ALD. Alcohol-mediated hepatocarcinogenesis is also discussed in the presence or absence of co-morbidities such as viral hepatitis C as well as therapeutic the role of innate immunity in ALD-HCV. Moreover, emphasis was placed on alcohol and drug interactions, as well as liver transplantation for end-stage ALD. Finally, the time came to eradicate alcohol-induced liver and intestinal damage by using betaine.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatopatías Alcohólicas Límite: Humans Idioma: En Revista: Exp Mol Pathol Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatopatías Alcohólicas Límite: Humans Idioma: En Revista: Exp Mol Pathol Año: 2015 Tipo del documento: Article